RecruitingNot ApplicableNCT04370730

Dimensional and Developmental Profiles of Psychosis in Children and Adolescents

Dimensional and Developmental Approach to Psychotic Episodes in Children and Adolescents: Impact on Clinical Management

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

200 participants

Start Date

Jun 2, 2021

Study Type

INTERVENTIONAL

Conditions

Schizophrenia Psychotic Disorders

Summary

Five collaborating sites in France will study the broad spectrum of schizophrenia in children and adolescents. Patients will be studied with diagnostic interviews, developmental histories, dimensional clinical ratings, comprehensive cognitive assessments, neuroimaging and DNA (copy number variant) analyses (in families and patients who agree), and follow-up of course of illness, cognitive status and treatment response to specific antipsychotic drugs. The goal of the study is to test a prior hypothesis about clinical subgroups in this population and to test whether these subgroups predict antipsychotic medication response.

Eligibility

Min Age: 7 YearsMax Age: 20 Years

Inclusion Criteria10

Children and young adults ages 7-20 years with age of onset of psychotic disorder between 7-17 years.
Hospitalized or seen for out-patient treatment for a psychotic episode, acute or chronic.
DSM-V diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder not otherwise specified, or major depressive episode with psychotic features.
Written informed consent signed by the parents or the individual(s) with legal parental authority, and by the minor patient if his/her condition permits.
Written informed consent signed by the patient if he/she is a major, after clinical stabilization (not delusional).
Has health insurance coverage from Social Security (France) (not AME coverage).
Parents : no specific criteria.
Siblings : siblings are eligible to participate if there are at least two first-degree relatives with psychotic disorders (including the patient) in the family.
Written informed consent for the genetic part of the study signed by any participating parents and siblings.
Has health insurance coverage from Social Security (France) (not AME coverage).

Exclusion Criteria5

Moderate or severe intellectual deficiency (IQ \< 50).
Psychoses judged to be secondary to medical illness, medication effects or drugs of abuse.
Diagnosis of bipolar disorder.
Patients who are under legal guardianship.
For the neuroimaging part of the study only : any contraindications to Magnetic Resonance Imaging.

Interventions

OTHERclinical, neuroimaging and DNA assessments

Selected assessments, including evaluation of treatment response to specific antipsychotic drugs, will be performed at follow-up visits after 1, 3 and 5 years